'DIMming' cancer growth -- STAT: Diindolylmethane suppresses ovarian cancer

January 26, 2012 in Cancer

Ovarian cancer is a major cause of death worldwide. Approximately 25,000 women will be diagnosed with ovarian cancer this year and 15,000 women will die from it in the United States alone. The novel anti-cancer drug diindolylmethane (DIM) has been shown in laboratory to inhibit the growth of ovarian cancer cells. New research published in BioMed Central's open access journal BMC Medicine has looked in detail at the action of DIM and showed that it works by blocking the activation and production of the transcription factor STAT3. DIM also enhances the anti-cancer effect of the platinum-based chemotherapy drug cisplatin.

Scientists from Texas Tech University Health Sciences Center, Amarillo already knew that DIM inhibited the growth of but have now found that DIM causes cell death (apoptosis). Not only was DIM able to kill cells but it also prevented and angiogenesis, both of which are necessary for a cancer to grow.

STAT are involved in the growth and survival of cells and are switched on by growth factors and immune system messengers (cytokines) such as IL-6. STAT3 is activated in 90% of ovarian cancers, however DIM was able to inhibit activation of STAT3 by preventing phosphorylation in response to IL-6. In a DIM also reduced the amount of IL-6 and the growth factor involved in angiogenesis (VEGF) in ovarian cancer cells.

Women with ovarian cancer are often treated with platinum containing . However patients treated with cisplatin often relapse or fail to respond and cisplatin resistance is known to be associated with an increase in STAT3. In this study the combination of cisplatin and DIM suppressed tumour growth in mice by an extra 50% compared to cisplatin alone.

Prof Sanjay K. Srivastava and Prabodh K. Kandala who performed the research explained, "DIM increases the effect of cisplatin, without being toxic to normal ovarian cells, by targeting STAT3 signaling and increasing apoptosis. Cisplatin is very toxic and has severe side effects. If co-treatment with DIM means that a low dose of cisplatin can be given to patients without the loss of therapeutic effect, but with reduced side effects, it would represent a significant breakthrough in clinical practice."

More information: Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting STAT3, Prabodh K Kandala and Sanjay K Srivastava, BMC Medicine (in press)

Journal reference: BMC Medicine search and more info website

Provided by BioMed Central search and more info website

not rated yet  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

deatopmg
Jan 26, 2012

Rank: not rated yet
so does this mean that OTC DIM will now be taken away from us because of some big pharma patent?
Rank not rated yet
Relevant PhysicsForums posts

More news stories

Key find for early bladder cancer treatment

Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.

Cancer created 2 hours ago | popularity 5 / 5 (1) | comments 0

Cold plasma successful against brain cancer cells

For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized ...

Cancer created 2 hours ago | popularity 5 / 5 (1) | comments 0 | with audio podcast

Non-Hodgkin lymphoma survival doubles since early 1970s

More than half of patients diagnosed with Non-Hodgkin Lymphoma (NHL) are now surviving the disease thanks to improved diagnosis and treatment, according to a new report1 from Cancer Research UK.

Cancer created 3 hours ago | popularity 5 / 5 (1) | comments 0

Researchers find possible 'master switch' in deadly brain cancer

(Medical Xpress)—Researchers at the University of Virginia School of Medicine have identified a promising target for treating glioblastoma, one that appears to avoid many of the obstacles that typically frustrate efforts ...

Cancer created 3 hours ago | popularity 3.5 / 5 (2) | comments 0 | with audio podcast

American cancer society celebrates 100 years of progress

(HealthDay)—The American Cancer Society, which is celebrating on Wednesday a century of fighting a disease once viewed as a death sentence, is making a pledge to put itself out of business.

Cancer created 17 hours ago | popularity not rated yet | comments 0


Researchers suggest boosting body's natural flu killers

A known difficulty in fighting influenza (flu) is the ability of the flu viruses to mutate and thus evade various medications that were previously found to be effective. Researchers at the Hebrew University of Jerusalem have ...

Anxious men fare worse during job interviews, study finds

Nervous about that upcoming job interview? You might want to take steps to reduce your jitters, especially if you are a man.

Second-generation TAVI device—Lotus Valve—shows good performance in REPRISE II

22 May 2013, Paris, France: The Lotus Valve, a second-generation transcatheter aortic valve implantation (TAVI) device, was successfully implanted in all of the first 60 patients in results from REPRISE II reported at EuroPCR ...

Major human drug trial underway for Alzheimer's

A potentially ground-breaking human drug trial is currently underway, which aims to discover whether blood pressure medication can slow or halt the progression of Alzheimer's Disease (AD). This is the latest ...

Pay attention: How we focus and concentrate

Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.

New discovery in fight against deadly meningococcal disease

Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.